97 related articles for article (PubMed ID: 21154164)
1. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers.
Alici E
Curr Opin Mol Ther; 2010 Dec; 12(6):724-33. PubMed ID: 21154164
[TBL] [Abstract][Full Text] [Related]
2. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals.
Foley B; De Santis D; Lathbury L; Christiansen F; Witt C
Int Immunol; 2008 Apr; 20(4):555-63. PubMed ID: 18308713
[TBL] [Abstract][Full Text] [Related]
3. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
4. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
Guo KY; Mei JZ; Yao KT
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
[TBL] [Abstract][Full Text] [Related]
5. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F; Bléry M; Bonnafous C; Zhang J; Clever D; Caligiuri MA; Farag SS
Blood; 2011 Dec; 118(24):6387-91. PubMed ID: 22031859
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Tai YT; Li XF; Catley L; Coffey R; Breitkreutz I; Bae J; Song W; Podar K; Hideshima T; Chauhan D; Schlossman R; Richardson P; Treon SP; Grewal IS; Munshi NC; Anderson KC
Cancer Res; 2005 Dec; 65(24):11712-20. PubMed ID: 16357183
[TBL] [Abstract][Full Text] [Related]
7. Tumor cells of non-hematopoietic and hematopoietic origins express activation-induced C-type lectin, the ligand for killer cell lectin-like receptor F1.
Akatsuka A; Ito M; Yamauchi C; Ochiai A; Yamamoto K; Matsumoto N
Int Immunol; 2010 Sep; 22(9):783-90. PubMed ID: 20663776
[TBL] [Abstract][Full Text] [Related]
8. Autologous and allogeneic HLA KIR ligand environments and activating KIR control KIR NK-cell functions.
Morvan M; David G; Sébille V; Perrin A; Gagne K; Willem C; Kerdudou N; Denis L; Clémenceau B; Folléa G; Bignon JD; Retière C
Eur J Immunol; 2008 Dec; 38(12):3474-86. PubMed ID: 19016529
[TBL] [Abstract][Full Text] [Related]
9. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
Romagné F; André P; Spee P; Zahn S; Anfossi N; Gauthier L; Capanni M; Ruggeri L; Benson DM; Blaser BW; Della Chiesa M; Moretta A; Vivier E; Caligiuri MA; Velardi A; Wagtmann N
Blood; 2009 Sep; 114(13):2667-77. PubMed ID: 19553639
[TBL] [Abstract][Full Text] [Related]
10. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity.
Ghio M; Contini P; Negrini S; Boero S; Musso A; Poggi A
Eur J Immunol; 2009 Dec; 39(12):3459-68. PubMed ID: 19830740
[TBL] [Abstract][Full Text] [Related]
11. NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients.
Johansson SE; Hejdeman B; Hinkula J; Johansson MH; Romagné F; Wahren B; Wagtmann NR; Kärre K; Berg L
Clin Immunol; 2010 Feb; 134(2):158-68. PubMed ID: 19880352
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
Romanski A; Bug G; Becker S; Kampfmann M; Seifried E; Hoelzer D; Ottmann OG; Tonn T
Exp Hematol; 2005 Mar; 33(3):344-52. PubMed ID: 15730858
[TBL] [Abstract][Full Text] [Related]
13. Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells.
Bernal M; Garrido P; Jiménez P; Carretero R; Almagro M; López P; Navarro P; Garrido F; Ruiz-Cabello F
Hum Immunol; 2009 Oct; 70(10):854-7. PubMed ID: 19580833
[TBL] [Abstract][Full Text] [Related]
14. HLA and KIR polymorphisms affect NK-cell anti-tumor activity.
Passweg JR; Huard B; Tiercy JM; Roosnek E
Trends Immunol; 2007 Oct; 28(10):437-41. PubMed ID: 17825623
[TBL] [Abstract][Full Text] [Related]
15. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
Mei JZ; Guo KY; Wei HM; Song CY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
[TBL] [Abstract][Full Text] [Related]
16. Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients.
Maat W; van der Slik AR; Verhoeven DH; Alizadeh BZ; Ly LV; Verduijn W; Luyten GP; Mulder A; van Hall T; Koning F; Jager MJ; van Bergen J
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2888-95. PubMed ID: 19234348
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell receptor--repertoire and functions after induction therapy by polyclonal rabbit anti-thymocyte globulin in unsensitized kidney transplant recipients.
Hadaya K; Avila Y; Valloton L; de Rham C; Bandelier C; Ferrari-Lacraz S; Pascual M; Pantaleo G; Martin PY; Buhler L; Villard J
Clin Immunol; 2010 Nov; 137(2):250-60. PubMed ID: 20719569
[TBL] [Abstract][Full Text] [Related]
18. NK cell natural cytotoxicity and IFN-gamma production are not always coordinately regulated: engagement of DX9 KIR+ NK cells by HLA-B7 variants and target cells.
Kurago ZB; Lutz CT; Smith KD; Colonna M
J Immunol; 1998 Feb; 160(4):1573-80. PubMed ID: 9469412
[TBL] [Abstract][Full Text] [Related]
19. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
Braud VM; Allan DS; O'Callaghan CA; Söderström K; D'Andrea A; Ogg GS; Lazetic S; Young NT; Bell JI; Phillips JH; Lanier LL; McMichael AJ
Nature; 1998 Feb; 391(6669):795-9. PubMed ID: 9486650
[TBL] [Abstract][Full Text] [Related]
20. Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells.
Zhang C; Zhang J; Sun R; Feng J; Wei H; Tian Z
Int Immunopharmacol; 2005 Jun; 5(6):1057-67. PubMed ID: 15829421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
